The value of internalizing CGP NGS testing for community oncology practice: A panel discussion

As CGP testing rates increase, community oncology practices are choosing to implement in-house testing. Many factors influence their decision on a suitable solution including, but not limited to panel content and attributes, oncologists’ preferences, lab expertise, and regulatory and reimbursement requirements. An expert panel discussion with a community-based pathologist, oncologist, and laboratory director will address:

• Parameters for consideration in assay selection (IVD vs LDT, RNA + DNA content, ease of implementation)
• Implementation data, process and feedback from two community site’s experience with the FDA-approved TruSight Oncology Comprehensive
• Value to network oncologists and patients

Thomas Stricker, MD
Technical Director, Center for Genomics and Molecular Studies
Tennessee Oncology
Medical Director, Precision Medicine
OneOncology

Kash Firozvi, MD
Oncologist, Medical Director of Cancer Services
Maryland Oncology Hematology

Ramaswamy Iyer, PhD
Lab Director
Maryland Oncology Hematology